Cascadian Therapeutics, Inc. (CASC)

Oncology Corporate Profile

Stock Performance

0.0000
0.0000

3 Month Stock History Chart

HQ Location

2601 Fourth Avenue, Suite 500
Seattle, WA 98121

Company Description

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. Our lead product candidate is tucatinib, an investigational, orally bioavailable, potent HER2-selective small molecule tyrosine kinase inhibitor (TKI).

Website: http://www.cascadianrx.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Stimuvax® / BLP25 liposome vaccineimmunotherapy2nd line metastatic Breast cancerIIIEMD Serono
PX-866PI3K inhibitor2nd line metastatic castrate-resistant prostate cancer (CRPC)II
PX-866PI3K inhibitor2nd line metastatic Glioblastoma Multiforme (GBM)II
ONT-380HER2 inhibitorBrain metastases from HER2+ Breast cancerIIArray
ONT-380HER2 inhibitorBreast cancerII
PX-12Trx-1 inhibitorPancreatic cancerII
Stimuvax® / BLP25 liposome vaccineimmunotherapyColorectal cancerIIMerck
Stimuvax® / BLP25 liposome vaccineimmunotherapyProstate cancerIIEMD Serono
PX-866PI3K inhibitor1st line metastatic Colorectal cancerI
PX-866PI3K inhibitor2nd line squamous cell carcinoma of Head & NeckI
ONT-10immunotherapyBreastICelldex
ONT-380 (+ tucatinib and T-DM1)HER2 inhibitorBreast cancerI
ONT-380 (+ tucatinib and capecitabine and trastuzumab)HER2 inhibitorBreast cancerI
PX-866PI3K inhibitorMelanomaI
PX-866PI3K inhibitorNon Small Cell Lung Cancer (NSCLC)I
PX-866PI3K inhibitorVarious cancer typesI
ONT-10 (+ varlilumab)immunotherapyVarious cancer typesICelldex
PX-478HIF-1 inhibitorVarious cancer typesI
PX-866PI3K inhibitorVarious cancer typesI

Source: http://www.cascadianrx.com/

Recent News Headlines

Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC)

6/8/2016 04:49 pm

(Cascadian Therapeutics) June 8, 2016 - The new name reflects the change in the Company’s focus from therapeutic vaccines to advancing targeted treatments for cancer.

Two Celgene Cancer Drugs Approved In Ireland

3/2/2016 12:01 pm

(Pharmafile [UK]) Mar 1, 2016 - Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory multiple myeloma patients; and Abraxane (nab-Paclitaxel) in combination with gemcitabine, as a first-line therapy for metastatic pancreatic cancer.

Venture Capitalists Invest $75M to Launch Forty Seven

2/25/2016 12:00 pm

(Wall Street Journal/Venture Capital Dispatch) Feb 24, 2016 - Venture capitalists are investing $75 million to launch Forty Seven Inc., a startup out of Stanford University that has joined a race to defeat cancer by engaging the immune system in the fight against tumors.

FDA to Begin Testing Foods For Glyphosate Residue

2/23/2016 12:00 pm

(Fox News) Feb 22, 2016 - Nearly a year after the World Health Organization (WHO) said glyphosate can “probably” cause cancer, the Food and Drug Administration (FDA) has announced that it will begin testing foods for residue of the most commonly used agricultural chemical in the world.

UK Kidney Cancer Patients Get Early Access to BMS' Opdivo

2/12/2016 07:02 am

(PharmaTimes [UK]) Feb 12, 2016 - UK patients with advanced kidney cancer are being given the opportunity to be treated with Bristol-Myers Squibb’s investigational immunotherapy Opdivo ahead of a licensing decision in Europe.

UK Lung Cancer Patients Get Early Access to BMS' Opdivo

2/5/2016 12:00 pm

(PharmaTimes [UK]) Feb 5, 2016 - UK regulators are granting some lung cancer patients access to Bristol Myers Squibb’s immunotherapy Opdivo ahead of a European licensing decision.

Want to Bet Immunotherapy Will Revolutionize Cancer? There's an ETF For That

10/14/2015 12:00 pm

(Forbes) Oct 14, 2015 - Now, for the first time, someone has come up with a similar way to bet on a trend within biotech – that immunotherapy is the next big thing for cancer.

Institute for Clinical Immuno-Oncology (ICLIO) Conference Spotlights Challenges & Strategies

10/14/2015 12:00 pm

(ACCCBuzz) Oct 13, 2015 - “The promise of immunotherapy that was seen 100 years ago is now a reality,” said ICLIO Advisory Committee Chair Lee Schwartzberg, MD, FACP, in remarks kicking off the first Institute for Clinical Immuno-Oncology Conference on Oct. 2, in Philadelphia.

Cancer Doctors Decline Pricey Drugs; Should Celgene Corporation And Eli Lilly Be Worried?

10/14/2015 12:00 pm

(Bidness Etc) Oct 12, 2015 - Bidness Etc discusses if Celgene and Lilly would face troubled sales, as US doctors drop expensive cancer drugs with little or no effect.

Thousands of Cancer Patients Die Needlessly Due To Referral Delays

10/14/2015 12:00 pm

(The Guardian [UK]) Oct 13, 2015 - Researchers claim deaths could be reduced if UK GPs were given a greater awareness of cancer symptoms in order to reduce late diagnosis.

CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma

10/14/2015 12:00 pm

(StreetInsider) Oct 14, 2015 - CASI Pharmaceuticals, Inc. announces that its oncology drug candidate, ENMD-2076, has received Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of hepatocellular carcinoma (HCC), including fibrolamellar carcinoma (FLC), a rare type of HCC.

OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers

10/14/2015 12:00 pm

(TheStreet) Oct 14, 2015 - The Ontario Institute for Cancer Research together with Novera Therapeutics Inc., have announced a collaboration with Janssen Biotech, LLC, a Pharmaceutical company of Johnson & Johnson, to accelerate the development of promising small molecule drug candidates for haematological cancers.

Vanderbilt University School of Medicine and OPKO Health Collaborate on Genomics

10/14/2015 12:00 pm

(OPKO) Oct 13, 2015 - OPKO Health, Inc. announced today a collaboration among its subsidiary, BioReference Laboratories, Inc., the Department of Pathology, Microbiology, and Immunology and the Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC) to leverage large scale genomics testing for optimal cancer care.

CURE Media Group Adds International Waldenstrom’s Macroglobulinemia Foundation to Advocacy Spotlight Partnership Program

10/14/2015 12:00 pm

(PRWeb) Oct 13, 2015 - CURE Media Group today announced a new partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) to expand education and support for patients battling this rare type of non-Hodgkin’s lymphoma, their families and physicians.

Study: Bacterium That Causes Q Fever Linked to Non-Hodgkin Lymphoma

10/14/2015 11:05 am

(ASH) Oct 13, 2015 - The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology.

Loxo Oncology Announces First Patient Enrolled in LOXO-101 Phase 2 Basket Trial in Patients With Solid Tumors Harboring TRK Fusions

10/14/2015 11:05 am

(CNN Money) Oct 14, 2015 - New phase 1 data has been accepted for an oral, late-breaking presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

UCLA-led Study Shows Deadly Prostate Cancer Cells Have Stem Cell Qualities

10/14/2015 11:04 am

(UCLA) Oct 12, 2015 - Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have shown that the cells responsible for generating deadly prostate cancer share some genetic qualities with the tissue-specific stem cells that naturally reside in the healthy prostate.